RIGL
Price
$46.82
Change
-$0.32 (-0.68%)
Updated
Oct 14 closing price
Capitalization
922.04M
26 days until earnings call
Intraday BUY SELL Signals
RPRX
Price
$58.99
Change
+$2.42 (+4.28%)
Updated
Oct 14 closing price
Capitalization
25.99B
28 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RIGL vs RPRX

RIGL vs RPRX Comparison Chart in %
View a ticker or compare two or three
VS
RIGL vs. RPRX commentary
Oct 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RIGL is a Hold and RPRX is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for RIGL with price predictions
Oct 14, 2026

Momentum Indicator for RIGL turns negative, indicating new downward trend

RIGL saw its Momentum Indicator move below the 0 level on October 12, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 75 similar instances where the indicator turned negative. In 65 of the 75 cases, the stock moved further down in the following days. The odds of a decline are at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 59 cases where RIGL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.

The Moving Average Convergence Divergence Histogram (MACD) for RIGL turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In 30 of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RIGL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

Bullish Trend Analysis

Following a +2.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where RIGL advanced for three days, in 225 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

RIGL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 172 of 209 cases where RIGL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 12 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. RIGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.167) is normal, around the industry mean (26.782). P/E Ratio (2.922) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (3.146) is also within normal values, averaging (437.542).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 81 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RIGL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 87 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
a Summary for RPRX with price predictions
Oct 13, 2026

RPRX in downward trend: 10-day moving average crossed below 50-day moving average on September 21, 2026

The 10-day moving average for RPRX crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RPRX as a result. In 49 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 57%.

The Moving Average Convergence Divergence Histogram (MACD) for RPRX turned negative on September 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 30 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 59%.

RPRX moved below its 50-day moving average on September 10, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RPRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 49%.

The Aroon Indicator for RPRX entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RPRX's RSI Oscillator exited the oversold zone, 17 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 28 of 58 cases where RPRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 48%.

Following a +2.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where RPRX advanced for three days, in 177 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.

RPRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.804) is normal, around the industry mean (26.782). P/E Ratio (31.382) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (1.360) is also within normal values, averaging (9.059). RPRX's Dividend Yield (0.016) is considerably higher than the industry average of (0.000). P/S Ratio (12.870) is also within normal values, averaging (437.542).

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 36 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. RPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
RIGL vs RPRX: Fundamental Ratings
RIGL
RPRX
OUTLOOK RATING
1..100
4378
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
1
Undervalued
PROFIT vs RISK RATING
1..100
8136
SMR RATING
1..100
1297
PRICE GROWTH RATING
1..100
3841
P/E GROWTH RATING
1..100
876
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RPRX's Valuation (1) in the Pharmaceuticals Major industry is somewhat better than the same rating for RIGL (45) in the Biotechnology industry. This means that RPRX’s stock grew somewhat faster than RIGL’s over the last 12 months.

RPRX's Profit vs Risk Rating (36) in the Pharmaceuticals Major industry is somewhat better than the same rating for RIGL (81) in the Biotechnology industry. This means that RPRX’s stock grew somewhat faster than RIGL’s over the last 12 months.

RIGL's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for RPRX (97) in the Pharmaceuticals Major industry. This means that RIGL’s stock grew significantly faster than RPRX’s over the last 12 months.

RIGL's Price Growth Rating (38) in the Biotechnology industry is in the same range as RPRX (41) in the Pharmaceuticals Major industry. This means that RIGL’s stock grew similarly to RPRX’s over the last 12 months.

RPRX's P/E Growth Rating (6) in the Pharmaceuticals Major industry is significantly better than the same rating for RIGL (87) in the Biotechnology industry. This means that RPRX’s stock grew significantly faster than RIGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RIGLRPRX
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
68%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 2 days ago
48%
Momentum
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 7 days ago
57%
MACD
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 6 days ago
59%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 2 days ago
57%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 2 days ago
56%
Advances
ODDS (%)
Bullish Trend 6 days ago
82%
Bullish Trend 3 days ago
56%
Declines
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 9 days ago
49%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 2 days ago
70%
Aroon
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 2 days ago
69%
COMPARISON
Comparison
Oct 15, 2026
Stock price -- (RIGL: $46.82 vs. RPRX: $58.99)
Brand notoriety: RIGL and RPRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RIGL: 48% vs. RPRX: 89%
Market capitalization -- RIGL: $922.04M vs. RPRX: $25.99B
RIGL [@Biotechnology] is valued at $922.04M. RPRX’s [@Biotechnology] market capitalization is $25.99B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RIGL’s FA Score shows that 1 FA rating(s) are green while RPRX’s FA Score has 3 green FA rating(s).

  • RIGL’s FA Score: 1 green, 4 red.
  • RPRX’s FA Score: 3 green, 2 red.
According to our system of comparison, RPRX is a better buy in the long-term than RIGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RIGL’s TA Score shows that 3 TA indicator(s) are bullish while RPRX’s TA Score has 5 bullish TA indicator(s).

  • RIGL’s TA Score: 3 bullish, 4 bearish.
  • RPRX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, RPRX is a better buy in the short-term than RIGL.

Price Growth

RIGL (@Biotechnology) experienced а -2.44% price change this week, while RPRX (@Biotechnology) price change was +3.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.52%. For the same industry, the average monthly price growth was -19.04%, and the average quarterly price growth was -19.99%.

Reported Earning Dates

RIGL is expected to report earnings on Nov 10, 2026.

RPRX is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Biotechnology (-8.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
RIGL
Daily Signal:
Gain/Loss:
RPRX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DCBO27.391.78
+6.95%
Docebo
MLI61.510.64
+1.05%
Mueller Industries Inc
MAN51.640.35
+0.68%
ManpowerGroup
FAMI0.11N/A
N/A
Farmmi Inc
GCL0.83-0.02
-2.18%
GCL GLOBAL HOLDINGS LTD

RPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RPRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RPRX jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RPRX
1D Price
Change %
RPRX100%
-2.09%
AXON - RPRX
48%
Loosely correlated
-0.26%
INCY - RPRX
45%
Loosely correlated
-2.46%
VRTX - RPRX
44%
Loosely correlated
-4.30%
RIGL - RPRX
41%
Loosely correlated
-3.42%
EXEL - RPRX
37%
Loosely correlated
-0.52%
More